Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can less immunosuppression save kidneys after transplant?

NCT ID NCT00213590

Disease control Sponsor: University Hospital, Rouen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looked at whether giving kidney transplant patients a lower dose of the drug cyclosporine could protect their kidney function over time. 208 patients who were at least one year post-transplant and on stable medications took part. The goal was to balance preventing organ rejection while reducing drug side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
cyclosporine A (reduced dose) with mycophenolate mofetil
What this could lead to
If successful, this could help kidney transplant patients maintain better kidney function with fewer side effects from immunosuppressants.
What could go wrong
This is a completed Phase 3 trial, but results may not apply to all patients. Lowering immunosuppression could increase the risk of organ rejection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

208 people

The number who actually took part.

Start date

Apr 2000

Finished

Nov 2006

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * first or second renal graft * cadaveric renal graft * second year of renal transplantation * stable renal function * moderate renal dysfunction risk * bitherapy with cyclosporine A and mycophenolate mofetil * corticosteroid withdrawal since 3 months at less Exclusion Criteria: * 2 or more acute rejection episodes * PRA\> 80% * serum creatinine\> 250µmol/L * 24-hour proteinuria \> 1g * humoral rejection * vasculitis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney failure Kidney transplantation Primary prevention

Contacts and locations

Locations

  • CHU de ROUEN

    Rouen, 76031, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.